Related Experiment Videos
The metyrapone test in affective disorders and schizophrenia
Journal of Affective Disorders
|June 1, 1984
Summary
The metyrapone test assessed the hypothalamic-pituitary-adrenal (HPA) axis in major depressive illness, mania, and schizophrenia. HPA axis hypoactivity was infrequent, but exaggerated responses correlated with DST non-suppression in melancholia.
Area of Science:
- Neuroendocrinology
- Psychiatry
- Clinical Medicine
Background:
- The hypothalamic-pituitary-adrenal (HPA) axis is implicated in mood disorders.
- Previous research suggests potential HPA axis dysregulation in depression, mania, and schizophrenia.
Purpose of the Study:
- To investigate HPA axis activity using the metyrapone test in patients with major depressive illness (melancholia), mania, and schizophrenia.
- To explore the relationship between metyrapone test responses and dexamethasone suppression test (DST) non-suppression in melancholia.
Main Methods:
- The metyrapone test was administered to patients diagnosed with major depressive illness (melancholia), mania, and schizophrenia.
- Results were analyzed to assess HPA axis function.
Main Results:
- Hypoactivity of the HPA axis, as indicated by the metyrapone test, was found to be infrequent in patients with affective disorders and schizophrenia.
- High normal or exaggerated responses to metyrapone were observed and appeared to correlate with DST non-suppression in patients with melancholia.
Conclusions:
- HPA axis hypoactivity is not a common finding in major depressive illness with melancholia, mania, or schizophrenia.
- Exaggerated metyrapone test responses may be linked to DST non-suppression in melancholic depression, suggesting a specific neuroendocrine profile.